Rainbow Childrens Medicare Limited (RAINBOW) Q2 FY27 Financial Results: PAT ₹625 Cr & Revenue ₹4,700 Cr(3 announcements)

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF
MetricValue
Revenue₹4,700 Cr
Net Profit (PAT)₹625 Cr
📢 Key Event
Rainbow Children's Medicare reported Q1 FY27 revenue of ₹4,700 crores, up 33.2% YoY.
🔄 What Changed
Revenue grew 33.2% YoY to ₹4,700 crores; PAT increased 16.2% YoY to ₹625 crores; EBITDA margin declined 71 bps to 28.6%.
🔮 What's Next
Operations at the new 100-bed Mumbai hospital are expected to commence in Q1 FY28.
💡 Investor Takeaway
The company delivered strong revenue and PAT growth with expanding hospital network and healthy cash reserves.

Rainbow Children's Medicare reported revenue of ₹4,700 crores for Q1 FY27, a 33.2% YoY increase, driven by strong hospital growth and operational efficiency. EBITDA rose to ₹1,346 crores with a margin of 28.6%, while PAT reached [amount context mismatch] crores, up 16.2% YoY. The company expanded into Mumbai with a new 100-bed hospital and acquired facilities in Nellore and Guntur to strengthen its Andhra Pradesh presence. Cash reserves stood at ₹6,129 crores as of June 30, 2026, supporting ongoing expansion plans.

2 Financial Results 🔴 High Importance Neutral 📄 PDF
MetricValue
Revenue₹4,827 Cr
Net Profit (PAT)₹625.4 Cr
🔮 What's Next
Expansion into North-East and Coimbatore with 150-1,040 new beds by H2 FY28.
💡 Investor Takeaway
Strong revenue and PAT growth signals effective expansion in pediatric and perinatal care, supported by institutional backing.

Rainbow Children's Medicare reported Q1 FY27 revenue of ₹4,699.9 crores and PAT of [amount context mismatch] crores, reflecting 13.4% YoY and 11.1% YoY growth respectively, driven by hospital network expansion across 13 cities and 24 locations. The company achieved JCI accreditation for three hospitals and fertility services, with occupancy at 67.2% and ALOS at 4,910 days. Strategic investments in tier-II cities and specialized perinatal care underpin growth, while institutional investors hold 55.8% combined stake. Expansion into North-East and Coimbatore is underway, targeting 150-1,040 new beds by H2 FY28.

3 Financial Results 🔴 High Importance Neutral 📄 PDF
📢 Key Event
Rainbow Children's Medicare reported Q1 FY26-27 revenue growth of 11.1% and EBITDA growth of 11.4% year-on-year.
🔄 What Changed
Revenue grew 11.1% and EBITDA grew 11.4% year-on-year.
🔮 What's Next
Upcoming hospital openings in Gurugram Sector 56 and 44 (NCR), Nellore and Guntur (Andhra Pradesh), and Indore (100-bed facility by end FY29).
💡 Investor Takeaway
The company is scaling its pediatric network with strong growth metrics and strategic expansion into new regions and specialties.

Rainbow Children's Medicare reported Q1 FY26-27 revenue growth of 11.1% and EBITDA growth of 11.4% year-on-year, driven by expansion in its pediatric and perinatal network across 24 hospitals in 13 cities, with promoter holding at 49.8% and mutual funds/AIFs at 19.9%. The company highlighted accreditations including JCI for multiple facilities and NABH for 14 hospitals, alongside strategic acquisitions like Prashanthi Hospital in Warangal and Pratiksha Hospital in Guwahati, supporting its hub-and-spoke model for specialized pediatric care.

About Rainbow Childrens Medicare Limited (RAINBOW)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹14,649.91 Cr P/E: 51.3 ROE: 17.4% ROCE: 27.1% Div Yield: 0.24%

View full RAINBOW stock details →

📡 Get AI alerts when RAINBOW files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RAINBOW — Free

📊 More RAINBOW filings

See all RAINBOW filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when RAINBOW files new disclosures

Track RAINBOW filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RAINBOW — Free

Free account · 2 AI queries/day